The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an ...

The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi ...

The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.

Prosecutors say the company filled unnecessary prescriptions that fueled the opioid epidemic. A spokesperson for CVS said the company admitted to no wrongdoing and “strongly disagreed” with the case’s ...

An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is ...

A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one ...

Yet one factor remains consistently underestimated: physical connectivity or fluid management. The tubing, connectors, ...

Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.

One lawyer involved noted how it's yet another example of Paragon and key investor Fairmount — which have helped transform ...

In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein ...

Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.

A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is ...